Hip fracture Recombinant human erythropoietin Elderly hip fracture Allogeneic blood transfusion Postoperative Blood Loss
Conditions
Interventions
An intravenous injection of 10,
000 IU of recombinant human erythropoietin (HemaplusR,
Apexcela,
Zuellig pharmacy) once on admission,An intravenous of 1 ml normal saline solution
Active Comparator Drug,Placebo Comparator Drug
intravenous human erythropoietin,Placebo
Sponsors
Ramathibodi hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) aged over 60 years 2) having low-energy trauma 3) having no contraindication for hip fracture surgery 4) willing to participate into this study
Exclusion criteria
Exclusion criteria: 1) delayed presentation more than 5 days after having injury 2) having myeloproliferative disorder 3) having uncontrolled hypertension 4) having serum creatinine > 2.0 mg/dL 5) having coagulopathy or taking anticoagulant therapy 6) having hemochromatosis 7) having inflammatory arthritis 8) allergic to rHuEPO or intravenous iron sucrose
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total hemoglobin loss day 3 Preop hemoglobin+total blood in-postop hemoglobin | — |
Secondary
| Measure | Time frame |
|---|---|
| Total hemoglobin loss 2 weeks Preop hemoglobin+total blood in-postop hemoglobin,blood transfusion rate 3 days unit of blood component | — |
Countries
thailand
Contacts
Public ContactPaphon Sa-ngasoongsong
Ramathibodi hospital, Mahidol university
Outcome results
None listed